Evolution of Precision Oncology, Personalized Medicine, and Molecular Tumor Boards

被引：2

作者：

Fujiwara, Yu ^{[1
]}

Kato, Shumei ^{[2
,3
]}

Kurzrock, Razelle ^{[4
,5
,6
,7
]}

机构：

[1] Roswell Pk Comprehens Canc Ctr, Dept Med, Elm & Carlton St, Buffalo, NY 14263 USA

[2] Univ Calif San Diego, Moores Canc Ctr, Ctr Personalized Canc Therapy, 3855 Hlth Sci Dr, La Jolla, CA 92093 USA

[3] Univ Calif San Diego, Moores Canc Ctr, Dept Med, Div Hematol & Oncol, La Jolla, CA USA

[4] Med Coll Wisconsin, Genom Sci & Precis Med Ctr, Froedtert & Med Coll Wisconsin Canc Ctr, 9200 West Wisconsin Ave, Milwaukee, WI 53226 USA

[5] John A Mellowes Ctr Genom Sci & Precis Med, 9200 West Wisconsin Ave, Milwaukee, WI 53226 USA

[6] WIN Consortium, Paris, France

[7] Univ Nebraska, Lincoln, NE USA

来源：

SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA | 2024年 / 33卷 / 02期

关键词：

Histology-agnostic; Personalized medicine; Personalized oncology; Precision medicine; Tumor-agnostic; CELL LUNG-CANCER; DABRAFENIB PLUS TRAMETINIB; METASTATIC BREAST-CANCER; POSITIVE SOLID TUMORS; PHASE-II; COMBINATION THERAPY; OPEN-LABEL; TRIAL; PEMBROLIZUMAB; CHEMOTHERAPY;

D O I：

10.1016/j.soc.2023.12.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

With multiple molecular targeted therapies available for patients with cancer that correspond to a specific genetic alteration, the selection of the best treatment through discussion is essential to ensure therapeutic efficacy. MTBs play a key role in this decision -making process to deliver personalized medicine to patients with cancer in a multidisciplinary manner. Historically, personalized medicine has been offered to patients with advanced cancer, but the incorporation of molecular targeted therapies and immunotherapy into the perioperative setting requires clinicians, including surgeons, to understand the role of the MTB. Evidence is accumulating to support the feasibility and survival benefit in patients treated with the matched therapy proposed by the MTB, and the MTB will continue to play an integral role in incorporating the growing body of evidence of cancer therapy to provide personalized treatment for each patient with cancer.

引用

页码：197 / 216

页数：20

共 91 条

[1] Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration [J].

Abida, Wassim ;

Patnaik, Akash ;

Campbell, David ;

Shapiro, Jeremy ;

Bryce, Alan H. ;

McDermott, Ray ;

Sautois, Brieuc ;

Vogelzang, Nicholas J. ;

Bambury, Richard M. ;

Voog, Eric ;

Zhang, Jingsong ;

Piulats, Josep M. ;

Ryan, Charles J. ;

Merseburger, Axel S. ;

Daugaard, Gedske ;

Heidenreich, Axel ;

Fizazi, Karim ;

Higano, Celestia S. ;

Krieger, Laurence E. ;

Sternberg, Cora N. ;

Watkins, Simon P. ;

Despain, Darrin ;

Simmons, Andrew D. ;

Loehr, Andrea ;

Dowson, Melanie ;

Golsorkhi, Tony ;

Chowdhury, Simon .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (32) :3763-+

[2] From Tissue-Agnostic to N-of-One Therapies:(R)Evolution of the Precision Paradigm [J].

Adashek, Jacob J. ;

Subbiah, Vivek ;

Kurzrock, Razelle .

TRENDS IN CANCER, 2021, 7 (01) :15-28

[3] Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study [J].

Ahn, Eugene R. ;

Rothe, Michael ;

Mangat, Pam K. ;

Garrett-Mayer, Elizabeth ;

Ali-Ahmad, Hussein M. ;

Chan, John ;

Maitland, Michael L. ;

Patel, Sapna R. ;

Reese, Zachary ;

Balmanoukian, Ani S. ;

Drescher, Charles W. ;

Li, Rui ;

Tsimberidou, Apostolia M. ;

Leath, Charles A., III ;

O'Lone, Raegan ;

Grantham, Gina N. ;

Halabi, Susan ;

Schilsky, Richard L. .

JCO PRECISION ONCOLOGY, 2023, 7

[4] Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study [J].

Alva, Ajjai S. ;

Mangat, Pam K. ;

Garrett-Mayer, Elizabeth ;

Halabi, Susan ;

Hansra, Damien ;

Calfa, Carmen J. ;

Khalil, Maged F. ;

Ahn, Eugene R. ;

Cannon, Timothy L. ;

Crilley, Pamela ;

Fisher, Julie G. ;

Haslem, Derrick S. ;

Shrestha, Sagun ;

Antonelli, Kaitlyn R. ;

Butler, Nicole L. ;

Warren, Sasha L. ;

Rygiel, Andrew L. ;

Ranasinghe, Shamika ;

Bruinooge, Suanna S. ;

Schilsky, Richard L. .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (22) :2443-+

[5] FDAApproval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer [J].

Arora, Shaily ;

Balasubramaniam, Sanjeeve ;

Zhang, Hui ;

Berman, Tara ;

Narayan, Preeti ;

Suzman, Daniel ;

Bloomquist, Erik ;

Tang, Shenghui ;

Gong, Yutao ;

Sridhara, Rajeshwari ;

Turcu, Francisca Reyes ;

Chatterjee, Deb ;

Saritas-Yildirim, Banu ;

Ghosh, Soma ;

Philip, Reena ;

Pathak, Anand ;

Gao, Jennifer J. ;

Amiri-Kordestani, Laleh ;

Pazdur, Richard ;

Beaver, Julia A. .

ONCOLOGIST, 2021, 26 (01) :E164-E172

[6] Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma [J].

Bajorin, D. F. ;

Witjes, J. A. ;

Gschwend, J. E. ;

Schenker, M. ;

Valderrama, B. P. ;

Tomita, Y. ;

Bamias, A. ;

Lebret, T. ;

Shariat, S. F. ;

Park, S. H. ;

Ye, D. ;

Agerbaek, M. ;

Enting, D. ;

McDermott, R. ;

Gajate, P. ;

Peer, A. ;

Milowsky, M., I ;

Nosov, A. ;

Antonio Jr, J. N. ;

Tupikowski, K. ;

Toms, L. ;

Fischer, B. S. ;

Qureshi, A. ;

Collette, S. ;

Unsal-Kacmaz, K. ;

Broughton, E. ;

Zardavas, D. ;

Koon, H. B. ;

Galsky, M. D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (22) :2102-2114

[7] I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy [J].

Barker, A. D. ;

Sigman, C. C. ;

Kelloff, G. J. ;

Hylton, N. M. ;

Berry, D. A. ;

Esserman, L. J. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 86 (01) :97-100

[8] A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group [J].

Bartoletti, Michele ;

Bergamini, Alice ;

Giannone, Gaia ;

Nero, Camilla ;

Musacchio, Lucia ;

Farolfi, Alberto ;

Passarelli, Anna ;

Kuhn, Elisabetta ;

Castaldo, Daniele ;

Lombardo, Valentina ;

Di Palma, Teresa ;

Lorusso, Domenica ;

Puglisi, Fabio ;

De Giorgi, Ugo ;

Valabrega, Giorgio ;

Schettino, Clorinda ;

Scambia, Giovanni ;

Capoluongo, Ettore ;

Pignata, Sandro .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 (09) :1205-1207

[9] Adjuvant trastuzumab: A milestone in the treatment of HER-2-positive early breast cancer [J].

Baselga, Jose ;

Perez, Edith A. ;

Pienkowski, Tadeusz ;

Bell, Richard .

ONCOLOGIST, 2006, 11 :4-12

[10] PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer [J].

Cercek, Andrea ;

Lumish, Melissa ;

Sinopoli, Jenna ;

Weiss, Jill ;

Shia, Jinru ;

Lamendola-Essel, Michelle ;

El Dika, Imane H. ;

Segal, Neil ;

Shcherba, Marina ;

Sugarman, Ryan ;

Stadler, Zsofia ;

Yaeger, Rona ;

Smith, J. Joshua ;

Rousseau, Benoit ;

Argiles, Guillem ;

Patel, Miteshkumar ;

Desai, Avni ;

Saltz, Leonard B. ;

Widmar, Maria ;

Iyer, Krishna ;

Zhang, Janie ;

Gianino, Nicole ;

Crane, Christopher ;

Romesser, Paul B. ;

Pappou, Emmanouil P. ;

Paty, Philip ;

Garcia-Aguilar, Julio ;

Gonen, Mithat ;

Gollub, Marc ;

Weiser, Martin R. ;

Schalper, Kurt A. ;

Diaz, Luis A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (25) :2363-2376

← 1 2 3 4 5 6 7 8 9 10 →